Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Innodata Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Innodata Inc trades at $67.34 (market cap $2.19B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.7× Innodata Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals.
| BIO | INOD | |
|---|---|---|
Market Cap | $8.04B | $2.19B |
Sector | Health | Technology |
52-Week High | $339.75 | $121.50 |
52-Week Low | $241.71 | $34.45 |
Enterprise Value | $7.85B | $2.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
INOD trades at $68.12, up 0.47% today but down 33% over the past month. The stock shows strong fundamentals with revenue growth to $252M in 2025 and net income of $32M, while beating EPS estimates in recent quarters. Technical indicators signal a bearish trend, with resistance at $69 and support at $67. Recent news highlights AI-driven growth and a new CFO appointment.
Outlook remains positive due to AI demand and raised guidance, but high valuation (P/E 59.89) and customer concentration pose risks. Analyst consensus is bullish with a $130 price target, suggesting significant upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
